Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.52 |
| ▸ | CTSK | P43235 | 9/20 | 0.52 |
| ▸ | CTSB | P07858 | 4/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16064303 | 1.00 | CTSS (0.52) | CTSSCTSKCTSBAAK1CTSL | |
| SCHEMBL19154996 | 0.87 | CTSS (0.52) | CTSSCTSKCTSBCTSLTRPA1 | |
| SCHEMBL31757716 | 0.86 | CTSL (0.52) | CTSSCTSKCTSBCTSLTRPA1 | |
| SCHEMBL16064145 | 0.86 | CTSK (0.51) | CTSSCTSKCTSBCTSLTRPA1 | |
| SCHEMBL24981989 | 0.85 | CTSS (0.51) | CTSSCTSKCTSBAAK1CTSL | |
| SCHEMBL28989469 | 0.85 | CTSS (0.51) | CTSSCTSKCTSBAAK1CTSL | |
| SCHEMBL24981565 | 0.84 | CTSS (0.45) | CTSSCTSKCTSBAAK1CTSL | |
| SCHEMBL30738857 | 0.83 | CTSK (0.49) | CTSSCTSKCTSBCTSL | |
| SCHEMBL16064072 | 0.81 | CTSS (0.53) | CTSSCTSKCTSBAAK1 | |
| SCHEMBL16447830 | 0.81 | CTSS (0.53) | CTSSCTSKCTSBAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265452-B1 | PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS | Neuprozyme Therapeutics ApS (DK) | 2020-03-04 | — | — | EP | disclosed |
| US-10479781-B2 | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors | Neuprozyme Therapeutics ApS (DK) | 2019-11-19 | — | — | US | disclosed |
| US-20180044328-A1 | PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS | PROZYMEX A/S (DK) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479781-B2 | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors | DPP4, DPP3, DPP8 | CTSS 444/4885CTSK 261/4885CTSB 184/4885 |
| US-20180044328-A1 | PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS | DPP4, DPP3, DPP8 | CTSS 326/4885CTSK 237/4885CTSB 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.